DAY ONE BIOPHARMACEUTICALS I (DAWN) Forecast, Price Target & Analyst Ratings
NASDAQ:DAWN • US23954D1090
21.27 USD
0 (0%)
Last: Mar 13, 2026, 10:42 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DAY ONE BIOPHARMACEUTICALS I (DAWN).
Forecast Snapshot
Consensus Price Target
$23.59
+ 10.90% Upside
Next Earnings Forecast
Release DateMay 1, 2026
PeriodQ1 / 2026
EPS Estimate-$0.29
Revenue Estimate55.987M
ChartMill Buy Consensus
82.67%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$23.59
Upside
+ 10.90%
From current price of $21.27 to mean target of $23.59, Based on 15 analyst forecasts
Low
$17.17
Median
$24.99
High
$30.45
Price Target Revisions
1 Month
2.02%
3 Months
3.93%
Price Target Summary
15 Wall Street analysts provided a forecast for the next 12 months for DAWN. The average price target is 23.59 USD. This implies a price increase of 10.9% is expected in the next year compared to the current price of 21.27.
The average price target has been revised upward by 3.93% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.67%
DAWN was analyzed by 15 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about DAWN.
In the previous month the buy percentage consensus was at a similar level.
DAWN was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2026-03-10 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2026-03-09 | Wedbush | Downgrade | Outperform -> Neutral |
| 2026-03-06 | Jones Trading | Downgrade | Buy -> Hold |
| 2026-03-06 | Needham | Downgrade | Buy -> Hold |
| 2026-02-25 | Needham | Maintains | Buy -> Buy |
| 2026-02-25 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-13 | TD Cowen | Initiate | Buy |
| 2025-11-24 | Needham | Reiterate | Buy -> Buy |
| 2025-11-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-07 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-05 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-08-06 | Needham | Maintains | Buy -> Buy |
| 2025-08-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-07 | Needham | Maintains | Buy -> Buy |
| 2025-04-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-03-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-02-26 | Needham | Reiterate | Buy -> Buy |
| 2025-02-26 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-02-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-10 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-01-13 | Needham | Reiterate | Buy -> Buy |
| 2025-01-07 | B of A Securities | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 1, 2026
PeriodQ1 / 2026
EPS Estimate-$0.29
Revenue Estimate55.987M
Revenue Q2Q82.01%
EPS Q2Q18.04%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
8.97%
Revenue (3 Months)
7.95%
EPS (1 Month)
3.21%
EPS (3 Months)
9.95%
Next Earnings Summary
DAWN is expected to report earnings on 5/1/2026. The consensus EPS estimate for the next earnings is -0.29 USD and the consensus revenue estimate is 55.99M USD.
The next earnings revenue estimate has been revised upward by 7.95% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 131.161M | 158.182M 20.60% | 242.84M 53.52% | 308.64M 27.10% | 419.18M 35.82% | 543.58M 29.68% | 650.07M 19.59% | 784.75M 20.72% | 744.36M -5.15% | 803.34M 7.92% | ||
| EBITDA YoY % growth | -206.028M -40.30% | -215.708M -4.70% | -124.274M 42.39% | -56.299M 54.70% | -5.646M 89.97% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -206.064M -40.27% | -217.27M -5.44% | -127.75M 41.20% | -81.485M 36.22% | 3.861M 104.74% | 114.55M 2,866.85% | 173.17M 51.17% | 258.75M 49.42% | 318.32M 23.02% | 369.26M 16.00% | 403.75M 9.34% | |
| Operating Margin | N/A | -165.65% | -80.76% | -33.55% | 1.25% | 27.33% | 31.86% | 39.80% | 40.56% | 49.61% | 50.26% | |
| EPS YoY % growth | -2.38 -9.68% | -1.78 25.21% | -1.04 41.57% | -0.79 23.71% | -0.05 93.41% | 0.47 1,007.32% | 1.34 182.26% | 1.96 46.48% | 1.84 -6.11% | 2.14 16.07% | 2.32 8.35% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.29 18.04% | -0.16 43.28% | -0.11 43.33% | -0.07 68.04% |
| Revenue Q2Q % growth | 55.987M 82.01% | 59.291M 74.86% | 64.094M 61.06% | 72.567M 35.09% |
| EBITDA Q2Q % growth | -16.626M 58.69% | -9.445M 71.61% | -23.794M -9.85% | N/A |
| EBIT Q2Q % growth | -20.45M 50.20% | -17.631M 49.59% | -9.235M 61.92% | -437.835K 98.41% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
34.92%
EPS Next 5 Year
31.19%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
38.90%
Revenue Next 5 Year
32.96%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
DAY ONE BIOPHARMACEUTICALS I / DAWN Forecast FAQ
Can you provide the average price target for DAY ONE BIOPHARMACEUTICALS I stock?
15 analysts have analysed DAWN and the average price target is 23.59 USD. This implies a price increase of 10.9% is expected in the next year compared to the current price of 21.27.
What is the next earnings date for DAWN stock?
DAY ONE BIOPHARMACEUTICALS I (DAWN) will report earnings on 2026-05-01.
What are the consensus estimates for DAWN stock next earnings?
The consensus EPS estimate for the next earnings of DAY ONE BIOPHARMACEUTICALS I (DAWN) is -0.29 USD and the consensus revenue estimate is 55.99M USD.
Can you provide the analyst count for DAY ONE BIOPHARMACEUTICALS I stock?
The number of analysts covering DAY ONE BIOPHARMACEUTICALS I (DAWN) is 15.